Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results - AleAnna (NASDAQ:ANNA), Core & Main (NYSE:CNM) US stocks lower on Tuesday as Dow falls over 350 points while NASDAQ and S&P; 500 also decline. Energy shares up 1.7%, tech stocks down 1.1%.

Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results US stocks lower on Tuesday as Dow falls over 350 points while NASDAQ and S&P 500 also decline. Energy shares up 1.7%, tech stoc...

#ANNA #CNM #Equities #FEED #JZ #Mid-Morning #Market #Update #News #OTLK #PAVS

Origin | Interest | Match

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering Outlook Therapeutics (Nasdaq: OTLK) priced a public offering of 20,000,000 shares and accompanying warrants to buy 20,000,000 shares at a combined price of $0.25 per share/warrant, yielding aggregate gross proceeds of $5.0 million before fees.Each warrant is exercisable immediately at $0.25 and expires five years from issuance; the offering is expected to close on or about March 25, 2026.

#OTLK #OTLKW Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics Announces Proposed Public Offering Outlook Therapeutics (Nasdaq: OTLK) announced on March 23, 2026 that it has commenced a best-efforts public offering of common stock (or pre-funded warrants) and accompanying warrants exercisable for common stock. The offering is subject to market and other conditions and may not be completed.H.C. Wainwright is the exclusive placement agent. Net proceeds are intended primarily for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration (File No. 333-278340); a prospectus supplement will be filed with the SEC.

#OTLK #OTLKW Outlook Therapeutics Announces Proposed Public Offering

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) Outlook Therapeutics (Nasdaq: OTLK) provided a regulatory update after a Type A meeting with the U.S. FDA regarding the Dec 30, 2025 Complete Response Letter for its BLA for ONS-5010/LYTENAVA (bevacizumab-vikg). The meeting focused on the FDA’s outstanding substantial-evidence issue and potential paths to approval.NORSE TWO met its primary and key secondary endpoints with clinically meaningful, statistically significant visual-acuity improvements; NORSE EIGHT and other data were submitted as confirmatory evidence. The FDA identified no safety concerns. The company is evaluating regulatory options and continuing discussions to clarify confirmatory evidence and next steps toward potential U.S. approval.

#OTLK #OTLKW Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

www.stocktitan.net/news/OTLK/outlook-therap...

#OTLK gets rejected and drops after FDA proposal denial

Today’s most cited tickers with negative sentiment (last 24h):

#SPY: 15
#HIMS: 6
#OTLK: 6
#TLT: 5
#HOOD: 4
#IONQ: 4

Today’s most cited tickers with negative sentiment (last 24h):

#SPY: 12
#TSLA: 5
#SPX: 5
#OTLK: 4
#HIMS: 4
#NFLX: 4

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CORZ 52% OTM
2. #NBIS 51% OTM
3. #BMNR 41% OTM
4. #SOC 39% OTM
5. #OTLK 38% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CORZ, #OTLK, #IREN, #SMR, #UEC

#OptionFlow #OptionsTrading #Trading

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD Outlook Therapeutics (Nasdaq: OTLK) said the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for the resubmitted biologics license application for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD), indicating the application cannot be approved in its present form.The FDA noted one adequate and well-controlled study demonstrated efficacy but again requested confirmatory evidence of efficacy and did not specify what evidence would be acceptable. The resubmission was based on the NORSE clinical program (including NORSE TWO and NORSE EIGHT).Outlook said it is exploring U.S. approval pathways and continuing commercial expansion in Europe, where LYTENAVA received European Commission and MHRA marketing authorizations and became commercially available in Germany and the UK in June 2025.

#OTLK #OTLKW Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NBIS 51% OTM
2. #OTLK 38% OTM
3. #ONDS 25% OTM
4. #XPEV 25% OTM
5. #AMZN 22% OTM

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ONDS, #RKT, #OTLK, #VNDA, #LYV

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#NBIS, #OTLK, #ONDS, #XPEV, #U

#OptionFlow #OptionsTrading #Trading

Today’s most cited tickers with positive sentiment (last 24h):

#CETX: 24
#TSLA: 21
#ASTS: 17
#SPY: 17
#NVDA: 13
#SLS: 11
#AMZN: 10
#OTLK: 8
#NKE: 8
#BTC: 7
#NXXT: 7
#SLV: 7
#EKSO: 7
#MREO: 6
#AAPL: 6
#MU: 6
#GOOG: 5
#GOOGL: 5

#OTLK on upward trend as FDA decision looms for US market launch

Today’s most cited tickers with positive sentiment (last 24h):

#SLV: 23
#CETX: 21
#ASTS: 20
#TSLA: 16
#NXXT: 12
#SPY: 11
#SLS: 10
#NVDA: 9
#AAPL: 8
#GVH: 7
#AMZN: 7
#BTC: 7
#POET: 6
#GOOGL: 6
#MU: 6
#INTC: 6
#OTLK: 6
#GM: 5

Breaking News: ( NASDAQ: #OTLK ) Outlook Therapeutics Announces New Employment Inducement Grants

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 Outlook Therapeutics (Nasdaq: OTLK) reported fiscal 2025 results for the year ended September 30, 2025. The company recorded a net loss of $62.4 million ($1.79 per share) and $1.4 million of revenue from initial European sales of LYTENAVA in June 2025. Gross profit was reduced by increased reserves for short-dated inventory from UK shipments. Operating expenses fell year-over-year driven by lower R&D after completion of NORSE Eight, offset by higher SG&A from the European launch. Cash and equivalents were $8.1 million at September 30, 2025, plus $14.9 million net ATM proceeds received after the period. The FDA PDUFA goal date for ONS-5010 is December 31, 2025.

#OTLK #OTLKW Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today

#OTLK #OTLKW Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 Outlook Therapeutics (Nasdaq: OTLK) re-submitted its Biologics License Application (BLA) for ONS-5010 to the U.S. FDA on Nov 3, 2025 after receiving official minutes from an FDA Type A meeting held in September 2025. ONS-5010 is an investigational ophthalmic bevacizumab formulation proposed to be branded LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).The company said the resubmission is intended to resolve the outstanding issue identified in a Complete Response Letter (CRL) dated August 2025 and that it is accelerating commercial efforts in Europe while positioning for a potential near-term U.S. approval.

#OTLK #OTLKW Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

www.stocktitan.net/news/OTLK/outlook-therap...

FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 Biotech firm seeks FDA Type A meeting following complete response letter for ONS-5010 bevacizumab formulation. NORSE TWO trial met endpoints, but FDA requests confirmatory efficacy data.

#OTLK #OTLKW Outlook Therapeutics Requests Type A Meeting with FDA

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD Outlook Therapeutics (NASDAQ: OTLK) announced that the FDA has issued a Complete Response Letter (CRL) for ONS-5010/LYTENAVA™ (bevacizumab-vikg), their wet AMD treatment candidate. The FDA cannot approve the application in its current form due to lack of substantial evidence of effectiveness.The CRL highlighted that while the NORSE TWO trial met its primary endpoint, the NORSE EIGHT trial did not, leading to the FDA's recommendation for additional confirmatory efficacy evidence. Despite this setback in the U.S., LYTENAVA™ has already received Marketing Authorization in the European Union and UK, and has been commercially available in Germany and UK since June 2025 as the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment.

#OTLK #OTLKW Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update Outlook Therapeutics (NASDAQ: OTLK) reported its Q3 FY2025 financial results and achieved significant milestones. The company recorded its first commercial sales of LYTENAVA™ (bevacizumab gamma) in Europe, marking its transition to a commercial-stage company. For Q3, OTLK reported revenue of $1.5 million and a net loss of $20.2 million ($0.55 per share).The company has a crucial PDUFA date of August 27, 2025, for ONS-5010/LYTENAVA™ FDA approval in the United States. LYTENAVA™ is now commercially available in Germany and UK for wet AMD treatment, with first patients already dosed. The company ended the quarter with cash and equivalents of $8.9 million.

#OTLK #OTLKW Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

www.stocktitan.net/news/OTLK/outlook-therap...

Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment Watch new CEO Bob Jahr discuss Outlook Therapeutics' future in bevacizumab treatment for retina diseases. Access exclusive investor conference insights now.

#OTLK #OTLKW Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

www.stocktitan.net/news/OTLK/outlook-therap...

Breakthrough: Scotland NHS Approves First-Ever Licensed Bevacizumab Treatment for Wet AMD Patients First licensed ophthalmic bevacizumab secures 10-year UK market exclusivity. NHS Scotland patients gain access to new wet AMD treatment option. Learn more.

#OTLK #OTLKW Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

#OTLK launches Lytenava™ in the EU and UK, offering a new solution for wet age-related macular degeneration (wet AMD). This marks a key step in global vision care innovation.
#OutlookTherapeutics
prismmarketview.com/outlook-ther...

Breakthrough Eye Treatment: First-Ever Approved Bevacizumab for Wet AMD Now Available in Germany and UK LYTENAVA targets 2.8M annual European injections market. First approved ophthalmic bevacizumab for wet AMD launches in Germany/UK. See launch details.

#OTLK #OTLKW Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage Fresh capital raise includes warrants with 2:1 coverage at $1.40 strike price. Proceeds targeted for working capital needs. See complete offering terms.

#OTLK #OTLKW Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

www.stocktitan.net/news/OTLK/outlook-therap...

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common

#OTLK #OTLKW Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

www.stocktitan.net/news/OTLK/outlook-therap...